US trial finds Novavax vaccine 90.4% effective against COVID-19 variants

A US late stage trial finds the Novavax COVID-19 vaccine to be 90.4% effective. Novavax say the vaccine was found to be more than 93% effective against the predominant COVID-19 'variants of concern'.